A randomized, double‐blind, single‐dose study to assess bioequivalence of MB02 biosimilar after manufacturing iteration and reference bevacizumab
Abstract To investigate and compare the pharmacokinetic (PK) profiles of MB02 products, before and after optimizing the manufacturing process, and reference bevacizumab to establish bioequivalence between them. In this randomized, double‐blind, single dose, parallel study, 114 healthy male volunteer...
Saved in:
Main Authors: | C. Schwabe (Author), A. Cole (Author), A. Espigares‐Correa (Author), M. E. Beydon (Author), A. Florez‐Igual (Author), J. Queiruga‐Parada (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2023-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pooled analysis of three pharmacokinetic studies comparing biosimilar MB02 and reference bevacizumab
by: B. Miguel‐Lillo, et al.
Published: (2023) -
MB09, a denosumab biosimilar candidate: Biosimilarity demonstration in a phase I study in healthy subjects
by: Monika Tomaszewska‐Kiecana, et al.
Published: (2024) -
Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
by: Di Cao, et al.
Published: (2023) -
Exposure-response analysis using time-to-event data for bevacizumab biosimilar SB8 and the reference bevacizumab
by: Suemin Park, et al.
Published: (2024) -
An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
by: Zhou X, et al.
Published: (2021)